Back to Discover

IDYA · Biotech · Nasdaq · As of 21 Nov 2026

IDEAYA Biosciences, Inc. stock: filings, catalysts and timeline

Sign in to follow

AIR Score

0100
50

Cautious · 50 / 100

AIR confidence

Support behind the full AIR read.

What is this? →

How much data stands behind the whole AIR read — all five perspectives, not just the Discovery Gap. Each perspective reports how complete its inputs are, and these are combined in the same proportions as the AIR Score; a perspective AIR could not score adds nothing, so missing data lowers this figure. It describes the data, not the company.

The Discovery Gap

LOWHIGHVERY HIGH

Low

Gap confidence

How fully AIR could measure this Gap — separate from the AIR Score's confidence.

What is this? →

How fully AIR could measure both sides of the Discovery Gap: the documented progress (News flow) and market attention (Recognition). It takes the weaker of the two, and reads zero when either side has no measurement. It describes the data, not the company.

Five perspectives

  • FundamentalsWhat is this?Too few of the required measures on file

    How the business is doing on its own reported US-GAAP numbers — growth, margins, cash generation, balance-sheet strength, capital efficiency and dilution — compared with sector peers.

    Source: SEC XBRL financial statements.

  • ValueWhat is this?Too few of the required measures on file

    How the shares are priced against sector peers, against the company's own recent history, and against a simple cash-flow estimate, using the filing numbers and the current price. AIR shows this as a band, never as a target price.

    Source: SEC XBRL financial statements and end-of-day prices.

  • News flowWhat is this?Balanced

    What the company has documented recently: material 8-K events (contracts, deals, results, leadership changes) and FDA approvals, weighted by recency and type. A language model's reading of each 8-K helps classify whether it is positive or negative. Filings, not press or social media.

    Source: SEC EDGAR 8-K filings and FDA approvals.

  • MomentumWhat is this?Watch

    The longer-term market read: the trend in end-of-day prices, strength against the market and the sector, and trading volume over roughly the past three to twelve months. It is shown, never used to rank the Shortlist.

    Source: End-of-day prices.

  • SafetyWhat is this?Strong

    The risk side: leverage, liquidity, cash runway, dilution, revenue and margin swings, company size and pre-commercial status, negative 8-K events (including legal and regulatory ones), and share-price drawdown and volatility. Higher means fewer of those risk markers.

    Source: SEC XBRL financial statements, SEC EDGAR 8-K filings and end-of-day prices.

Rating words, not raw numbers.

How AIR scores →

Fundamental score not available. AIR's fundamental engine is built for businesses with established revenue and cash flow; biotech financial profiles — often R&D-heavy or pre-revenue — don't yet fit the measures it requires. AIR still assesses this company on News flow, Momentum and Safety, and the missing score lowers its AIR confidence.

Discovery Gap: Low (9/100) · Gap confidence 61/100

Discovery gap

The market has largely caught up to the documented story.

Low is the most common level — the cut-offs are fixed, and levels can shift as scores refresh.

What is this?

How far documented progress (News flow) runs ahead of market attention. Attention is measured from institutional holdings reported to the SEC, trading volume, price behaviour and how richly the shares are valued — not from social media or analyst ratings.

Source: SEC EDGAR filings (8-K and 13F), FDA approvals and end-of-day prices.

How levels work. The levels use fixed cut-offs, but market attention is ranked against the other ~1,800 companies AIR covers that day (valuation against the same sector). Documented progress counts filings from the past 18 months, newer ones weighing more; attention uses the latest quarter of institutional holdings, the last three to six months of trading, and six to twelve months of price behaviour. Many companies show a Low Gap or none at all — a gap needs filings that read more positively than neutral. A level can change from one day to the next as scores refresh and the other companies move.

This month at a glance

AIR Score™ change: -5Slipped -5 on softer inputs.
Window31 Oct 2026 → 21 Nov 2026
Momentum-5Weighed on the score this month.

Evidence timeline

What changed — last 90 days

As of 16 Nov 2026
  1. The company completed an NDA submission for darovasertib in metastatic uveal melanoma, presented supportive ESMO data across multiple indications, and initiated Phase 3 trials for IDE849.

    Results · 8-K filed 3 Nov →

  2. The company filed its quarterly report for the period ending September 30, 2026.

    Quarterly/annual report · 10-Q filed 3 Nov →

What the company disclosed, not verified by AIR · sources link to the Evidence timeline below.

  1. Expected
  2. Wed 17 Feb · expected 10-K

    Last year filed 17 Feb 2026.

  3. Wed 5 May · expected 10-Q

    Last year filed 5 May 2026.

  4. Filed
  5. Tue 3 Nov · 10-Q

    Quarterly report (10-Q), period ending 30 Sep 2026

    Gap Low · 1 → Medium · 12

    Progress is running ahead of attention.

    The price trend weakened.

  6. Tue 3 Nov · 8-K

    8-K · Item 2.02 — Results of operations

    IDEAYA completed NDA submission for darovasertib in metastatic uveal melanoma, presented supportive ESMO data across multiple indications, initiated Phase 3 trials for IDE849, and maintains $1.15B cash runway into 2030. Offset by OptimUM-010 trial closure and increased operating losses.

    Gap Low · 1 → Medium · 12

    Progress is running ahead of attention.

    The price trend weakened.

  7. Tue 4 Aug · 8-K

    8-K · Item 2.02 — Results of operations

  8. Tue 4 Aug · 10-Q

    Quarterly report (10-Q), period ending 30 Jun 2026

  9. Tue 23 Jun · 8-K

    8-K · Item 8.01 — Other events

  10. Wed 10 Jun · 8-K

    8-K · Item 8.01 — Other events

  11. Wed 3 Jun · 8-K

    8-K · Item 8.01 — Other events

  12. Mon 1 Jun · 8-K

    8-K · Item 8.01 — Other events

  13. Tue 5 May · 10-Q

    Quarterly report (10-Q), period ending 31 Mar 2026

  14. Tue 5 May · 8-K

    8-K · Item 2.02 — Results of operations

  15. Tue 5 May · 8-K

    8-K · Item 8.01 — Other events

  16. Mon 13 Apr · 8-K

    8-K · Item 8.01 — Other events

  17. Thu 9 Apr · 8-K

    8-K · Item 8.01 — Other events

  18. Tue 17 Feb · 8-K

    8-K · Item 2.02 — Results of operations

  19. Tue 17 Feb · 10-K

    Annual report (10-K), FY2025

  20. Mon 12 Jan · 8-K

    8-K · Item 8.01 — Other events

  21. Mon 12 Jan · 8-K

    Current report (8-K)

  22. Fri 12 Dec · 8-K

    8-K · Item 1.02 — Material agreement terminated

  23. Fri 5 Dec · 8-K

    8-K · Item 8.01 — Other events

  24. Tue 4 Nov · 10-Q

    Quarterly report (10-Q), period ending 30 Sep 2025

  25. Tue 4 Nov · 8-K

    8-K · Item 2.02 — Results of operations

  26. Mon 20 Oct · 8-K

    8-K · Item 8.01 — Other events

  27. Mon 8 Sep · 8-K

    8-K · Item 8.01 — Other events

Solid dots: a filing AIR classified as material. Grey: routine. Hollow: expected, from last year's dates — not a forecast.

Ask AIR

What would change our view

A weaker balance sheet in the next filing cycle, a material regulatory setback, or a new evidence cluster that re-opens a distance between filings and attention would move the score, and the page would show which one did.

Research, not tips. No buy/sell recommendations, no price forecasts. Every score is derived from public filings and market data — figures round to whole numbers and refresh each trading day.